Charles River Laboratories International, Inc. (CRL) Cash Flow Statement

The negative net income in 2026Q1 and Q2 is heavily influenced by non-cash charges, as evidenced by the large gap between net income and operating cash flow. In 2026Q2, operating cash flow of $179.7M against a net loss of $1.5M implies that the loss is largely non-cash, likely from impairments or write-downs. This suggests that the underlying cash-generative ability of the core business remains intact, but investors should monitor whether these non-cash charges recur.

The FCF trajectory is highly volatile, reflecting the lumpy nature of the business and the impact of working capital swings. The 2026Q1 negative FCF was driven by a significant working capital outflow of $106.1M, which reversed in Q2. This volatility suggests that quarterly FCF is not a reliable indicator of annual performance, and investors should focus on the cumulative trend, which appears stable but not growing.

The reduction in capital intensity suggests that management is prioritizing cash preservation amid revenue stagnation. However, this may also indicate a pause in expansionary projects, which could limit future growth capacity. The maintenance capex requirement appears manageable, but the low CapEx/Rev ratio may not be sustainable if the company needs to invest in modernization or regulatory compliance.

The large working capital outflow in 2026Q1 was likely due to timing of collections or inventory build-up, which reversed in Q2. This pattern suggests that the company's cash conversion cycle is not stable, and management may be using working capital management to smooth cash flows. Investors should monitor the efficiency of receivables and inventory, as any prolonged deterioration could signal operational issues.

The substantial share repurchases indicate management's confidence in the long-term value of the business, but they also consume cash that could be used for debt reduction or strategic investments. Given the negative net income and stagnant revenue, the buybacks may be an attempt to support EPS, but they increase financial leverage. Investors should assess whether this capital deployment is prudent given the current operational challenges.

The persistent gap between operating cash flow and net income underscores the impact of non-cash charges, such as impairments and depreciation, which depress reported earnings but do not affect cash generation. This suggests that the company's cash-generating ability is stronger than its earnings suggest, but it also raises questions about the quality of earnings and the sustainability of these non-cash charges. Investors should monitor whether this divergence narrows as the company works through its impairment cycle.